Towards Novel Potential Molecular Targets for Antidepressant and Antipsychotic Pharmacotherapies

Author:

Kositsyn Yuriy M.1234,de Abreu Murilo S.5ORCID,Kolesnikova Tatiana O.1236,Lagunin Alexey A.78ORCID,Poroikov Vladimir V.7ORCID,Harutyunyan Hasmik S.910ORCID,Yenkoyan Konstantin B.910ORCID,Kalueff Allan V.1234569

Affiliation:

1. Institute of Experimental Medicine, Almazov National Medical Research Centre, Ministry of Healthcare of Russian Federation, St. Petersburg 197341, Russia

2. Neurobiology Program, Sirius University of Science and Technology, Sirius Federal Territory 354340, Russia

3. Institute of Translational Biomedicine, St. Petersburg State University, St. Petersburg 199034, Russia

4. Laboratory of Preclinical Bioscreening, Granov Russian Research Center of Radiology and Surgical Technologies, Ministry of Healthcare of Russian Federation, Pesochny 197758, Russia

5. Neuroscience Group, Moscow Institute of Physics and Technology, Moscow 115184, Russia

6. Vivarium, Ural Federal University, Yekaterinburg 620049, Russia

7. Department of Bioinformatics, Institute of Biomedical Chemistry, Moscow 119121, Russia

8. Department of Bioinformatics, Pirogov Russian National Research Medical University, Moscow 117997, Russia

9. Neuroscience Laboratory, COBRAIN Center, Yerevan State Medical University Named after M. Heratsi, Yerevan 0025, Armenia

10. Department of Biochemistry, Yerevan State Medical University Named after M. Heratsi, Yerevan 0025, Armenia

Abstract

Depression and schizophrenia are two highly prevalent and severely debilitating neuropsychiatric disorders. Both conventional antidepressant and antipsychotic pharmacotherapies are often inefficient clinically, causing multiple side effects and serious patient compliance problems. Collectively, this calls for the development of novel drug targets for treating depressed and schizophrenic patients. Here, we discuss recent translational advances, research tools and approaches, aiming to facilitate innovative drug discovery in this field. Providing a comprehensive overview of current antidepressants and antipsychotic drugs, we also outline potential novel molecular targets for treating depression and schizophrenia. We also critically evaluate multiple translational challenges and summarize various open questions, in order to foster further integrative cross-discipline research into antidepressant and antipsychotic drug development.

Funder

Republic of Armenia State Committee of Science

European Union-funded H2020 COBRAIN project

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Reference249 articles.

1. Depression, W. (2017). Other Common Mental Disorders: Global Health Estimates, World Health Organization.

2. Depression and schizophrenia viewed from the perspective of amino acidergic neurotransmission: Antipodes of psychiatric disorders;Pilc;Pharmacol. Ther.,2019

3. Challenges of treatment-resistant depression;Pandarakalam;Psychiatr. Danub.,2018

4. Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives;Nucifora;Neurobiol. Dis.,2019

5. Zebrafish models: Do we have valid paradigms for depression?;Friend;J. Pharmacol. Toxicol. Methods,2018

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3